CREBBP and prostate cancer: Altogether, these findings suggest that p300/CBP retain partial catalytic function in the presence of bromodomain inhibitors and highlight the efficacy of CBPD-409 in completely extinguishing p300/CBP oncogenic histone acetylation program in prostate cancer cells.